Viewing nowCombinationSitafol MXR Slow Release Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.

MFDS item code 202202001 · Approved 2022.05.12 · Insurance code 622804870
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to help blood sugar control in patients with type 2 diabetes. When taken alongside dietary management and exercise therapy, it can effectively manage blood sugar levels. In particular, the two components, sitagliptin and metformin, work together to provide more stable blood sugar control. This helps prevent complications of diabetes. Therefore, this medication is used to enhance blood sugar control in patients with type 2 diabetes.
In antidiabetic therapy, the dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the feces, the healthcare professional should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions, 2. Do not administer to the following patients). 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients who were receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with this drug 50/1000 mg extended-release tablets, 2 tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be carried out. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), provided they have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because of its metformin component (see Precautions, 2. Do not administer to the following patients).
This medication is a drug used for the treatment of diabetes, containing two components. The first component helps to control blood sugar, but serious allergic reactions may occur in some patients, so caution is advised. If symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur within 3 months of taking the medication, discontinue use immediately and consult a physician. The second component lowers blood sugar but should not be administered to patients with poor kidney function or those experiencing severe infection or dehydration. Additionally, acute pancreatitis may develop, so if abdominal pain, vomiting, or severe abdominal discomfort occurs, immediately inform medical personnel. This medication should be taken with regular monitoring of kidney function, and if kidney function worsens rapidly or dehydration symptoms occur, use should be discontinued. Excessive alcohol consumption may increase the risk of side effects from this medication, so it is advisable to avoid alcohol. In situations such as surgery, severe infections, or trauma, the use of this medication should be temporarily suspended and resumed once the condition stabilizes. Additionally, this medication may cause hypoglycemia, so regular meals are important, and extra caution should be taken for hypoglycemic symptoms when taken with other blood sugar-lowering agents. It is advisable not to use this medication in pregnant or breastfeeding women or in children under 18 years of age, as safety has not been confirmed. Elderly patients may have a higher risk of decreased kidney function, therefore dosage adjustment and kidney function monitoring are necessary. During the use of this medication, it is important to routinely check blood sugar, kidney function, and conduct blood tests to monitor health status. If overdose is suspected, visit a hospital immediately for appropriate treatment; this medication can be partially removed through dialysis.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture and should ideally be kept at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's efficacy and ensure safe usage.
Bright green, oval-shaped slow-release film-coated tablet with a convex surface on both sides
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.